Transparency, or the practice of disclosing clinical trial data, is highly important in clinical research. What happens when companies decide to not publish all of their clinical trial results, and fall out of compliance with the FDAA? FDA regulatory attorney Darshan Kulkarni discusses the dangers of not being transparent, and the consequences facing companies who withheld their results.
A discussion with CRO CEO John Reites. Our discussion will explore decentralized clinical trials, the missing secret ingredient in clinical...
A discussion with health and clinical trial entrepreneur Zedrick Buhay on starting a clinical trial site, choosing studies and therapeutic...
A discussion on Project Management/Clinical Monitoring/Clinical Operations including on Clinical Development Training, recruitment and...
